Novartis generics subsidiary Sandoz made history ahead of the weekend after getting approval in the US for Zarxio, the first biosimilar cleared by the FDA. Zarxio (filgrastim-sndz) is a biosimilar ...

No details about pricing have been released by Sandoz yet, though it priced its first US biosimilar Zarxio at 15% discount to the originator drug Neupogen, another Amgen drug. Sandoz gave no ...

Alston & Bird represent plaintiff Sandoz Inc. in an antitrust lawsuit against Amgen. Munger, Tolles & Olson and Kaufman & Canoles represent Amgen in a related case in the Eastern District of Virginia.

Biosimilar Litigations include litigations relating to biosimilar/follow-on products of CDER-listed reference products. Litigations between biosimilar applicants/manufacturers and reference ...

The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant).

Insulin as part (rDNA origin) injection Novolog (Novo Nordisk) 28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days ...

Purpose. The efficacy and safety of granulocyte colony-stimulating factor (G-CSF) in critically ill patients with severe sepsis or septic shock were evaluated. Summary. The medical literature was ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.